title: Development and implementation of delivery and quality control system for cellular therapies: experience in 500 patients.
authors.affiliation: Cellcor Inc., Newton, MA 02159.
authors.forename: F
authors.initials: F
authors.lastname: Miesowicz
authors.forename: G
authors.initials: G
authors.lastname: du Moulin
authors.forename: V
authors.initials: V
authors.lastname: Liu
authors.forename: D
authors.initials: D
authors.lastname: Hamilton
authors.forename: B
authors.initials: B
authors.lastname: Davies
authors.forename: Z
authors.initials: Z
authors.lastname: Pitkin
authors.forename: J
authors.initials: J
authors.lastname: Stack
authors.forename: J
authors.initials: J
authors.lastname: Chew-Darke
authors.forename: M
authors.initials: M
authors.lastname: Osband
mesh_terms: D001804:Blood Transfusion, Autologous / Q000592:standards; D002292:Carcinoma, Renal Cell / Q000276:immunology / Q000628:therapy*; D006801:Humans; D016130:Immunophenotyping; D016219:Immunotherapy, Adoptive; D007680:Kidney Neoplasms / Q000276:immunology / Q000628:therapy*; D008213:Lymphocyte Activation; D017710:Lymphocyte Transfusion / Q000592:standards; D011786:Quality Control; D013601:T-Lymphocytes / Q000276:immunology*; D014481:United States